Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02191917 · ClinicalTrials.gov registry record
A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- 8
- Enrollment target
NCT02191917 is a clinical trial that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 8 participants.
The verdict
NCT02191917 was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .
Interventions
- PROCEDURE Respiratory muscle strength measurements by different techniques.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-10-21 |
| Est. Completion | 2016-06-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02191917
The ClinicalTrials.gov registry entry for NCT02191917 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Respiratory muscle strength measurements by different techniques. is the first listed.
NCT02191917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02191917 about?
NCT02191917 is a clinical study titled "A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)". Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .
What is the current status of trial NCT02191917?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2014-10-21. Estimated completion is 2016-06-22.
What interventions are being tested in trial NCT02191917?
The interventions under investigation include: Respiratory muscle strength measurements by different techniques. (PROCEDURE).
Who is sponsoring clinical trial NCT02191917?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.